Delfi Diagnostics: Thomas Russo
Delfi Diagnostics said that Thomas Russo has been appointed as CFO as the company expands into the blood-based liquid biopsy market with its FirstLook Lung cancer detection test. Russo had most recently worked as the CFO of pharmaceutical firm Icosavax, where he helped to guide the company through a growth period from its initial public offering through its acquisition by AstraZeneca. He also was the CFO of Assembly Biosciences, worked in senior finance and commercial operations roles at Gilead Sciences, and was an equity research senior analyst for biotechnology at Robert W. Baird & Co.
Quantum-Si: Todd Bennett, John Vieceli, Lindsay Thompson, Grace Johnston
Quantum-Si has appointed Todd Bennett as chief commercial officer. Bennett previously worked at life science firms including Luminex, Abbott, Roche, and Immucor. He will replace Grace Johnston who has resigned from her role as CCO. She will provide transitional support to the company through Sept. 6.
QSI also named John Vieceli chief product officer and Lindsay Thompson chief human resources officer. Vieceli joined QSI in December 2022. Prior to that, he held leadership roles at companies including Illumina, Omniome, and Pacific Biosciences. Thompson joined QSI in 2021. Before that, she held HR roles at companies in the life science, financial services, and distribution and manufacturing spaces.
Aditxt: Christopher Mitton
Aditxt, life sciences company developing technologies to improve immune system health through reprogramming and monitoring, said that it has appointed Christopher Mitton as president of the company's Pearsanta precision health subsidiary. Mitton continues to serve as CEO of MDNA Life Sciences, which sold its Mitomic blood-based early disease and cancer detection platform to Pearsanta in January. Prior to this, he headed sales at Cancer Genetics. He also led the North American commercial expansion for French molecular diagnostics company Ipsogen and subsequently managed the personalized healthcare portfolio at Qiagen, which acquired Ipsogen in 2011. Earlier in his career, Mitton held sales positions with BioChem Immunosystems, Abbott Diagnostics, and Bayer Healthcare. He holds a B.S. in molecular biology from Florida A&M University.
Eppendorf: Christine Munz
Eppendorf has appointed Christine Munz as the new CEO of the Eppendorf Group, effective Oct. 1. She will succeed Wilhelm Plüster, who will now take on other strategically relevant responsibilities at the company. Munz will join Eppendorf from Leica Biosystems, where she is currently VP and general manager of core histology and previously served as VP of life science. Munz also previously spent 17 years with Roche, culminating with the position of global head of product management.
BC Platforms: Jan Berger
BC Platforms has appointed Jan Berger as chair of its board of directors. She had been an independent board member since 2023. Berger leads Health Intelligence Partners, a consulting firm, and was previously executive VP as well as chief innovation and medical officer at CVS Health. She holds an M.D. as well as a master's in jurisprudence from Loyola University Chicago and is a pediatrician by training.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.